



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

627.AGGRESSIVE LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Myrna Candelaria, MD¹, Luis Mario Villela Martinez, MD², Brady E Beltran, MD³, Ana Florencia Ramirez, MD⁴, Marialejandra Torres Viera, MD⁵, Carolina Oliver, MD⁶, Henry Idrobo Quintero⁷, Fernando Perez-Jacobo, MD⁸, Guilherme Fleury Perini, MD⁹, Camila Peña, MD¹⁰, Laura Korin, MD¹¹, Denisse Castro, MD¹², Victoria Irigoín, MD¹³, Sally Rose Paredes, MD¹⁴, Jose A Hernandez-Hernandez, PhD¹⁵, Perla R. Colunga-Pedraza, MD¹⁶, David Gomez-Almaguer, MD¹⁷, Guillermo Ruiz-Argüelles, MD¹⁸, Melani Otañez¹⁹, Jorge J. Castillo, MD²⁰, Luis Enrique Malpica Castillo, MD²¹

¹Clinical Research, Instituto Nacional de Cancerología, Mexico city, Mexico

²Centro Medico Dr. Ignacio Chavez, Hermosillo, MEX

³Servicio Oncología Médica, Hospital Edgardo Rebagliati, Lima, Peru

⁴Instituto Nacional de Cancerología, MEXico city, Mexico

⁵Unidad Linfomas, Instituto Hematología y Oncología Universidad Central Venezuela, Caracas, Venezuela (Bolivarian Republic of)

⁶British Hospital, Montevideo, Uruguay

⁷Asociación Colombiana de Hematología y Oncología (ACHO), Bogotá, Colombia

⁸Hospital Central Norte PEMEX, MEXico city, Mexico

⁹Hospital Israelita Albert Einstein, São Paulo, Brazil

¹⁰Hospital Del Salvador, Santiago, Chile

¹¹Instituto Alexander Fleming, Buenos aires, Argentina

¹²Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

¹³Hospital De Clinicas, Montevideo, URY

¹⁴Hospital Nacional Edgardo Rebagliati Martins. Lima Peru, lima, Peru

¹⁵TEC Monterrey, Monterrey, MEX

¹⁶Servicio de Hematología, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Universidad Autónoma de Nuevo León, Monterrey, Mexico

¹⁷Servicio de Hematología, Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico

¹⁸Clinica Ruiz. Puebla, Puebla, Mexico

¹⁹Hospital de Alta Especialidad de Sonora, Sonora, Mexico

²⁰Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA

²¹Department of Lymphoma and Myeloma, University of Texas MD Anderson cancer Center, Houston, TX

Background: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma. DLBCL commonly affects patients with comorbidities and the elderly. To date, chemoimmunotherapy remains the standard of care for these patients. Data on patients aged ≥ 65 years managed in Latin America (LATAM) are scarce. Herein, we examine the clinical, treatment and outcome patterns in older patients with DLBCL, with a focus on the effect of treatment in survival outcomes.

Methods: We retrospectively analyzed patients aged ≥ 65 years with newly diagnosed DLBCL managed at different academic institutions in 8 LATAM countries. Demographic characteristics are reported using descriptive statistics. All patients received treatment; those who completed 6 cycles and underwent either CT or PETCT at the end of therapy were considered evaluable for response. Survival curves were estimated using the Kaplan-Meier method. Logistic and Cox proportional-hazard regression models were used to evaluate parameters associated with response and survival.

Results: A total of 651 patients were identified and had sufficient data for analysis; median age was 74.1 years (65-96), 335 (51.5%) were female, 400 (61.4%) had ECOG ≤ 1 , and 426 (65.4%) had advanced disease (stage III-IV). No difference in clinical

features and laboratory parameters were identified among patients aged <75 vs ≥75 years (Table). The most common first-line chemoimmunotherapy regimens used were standard dose R-CHOP (n=421, 64.7%), R-CVP (n= 74, 11.4 %), R-mini-CHOP (n= 61, 9.4%), and CHOP (n= 29, 4.5%). Eight patients (1.2%) received R-EPOCH, and 43 (6.6%) best supportive care including some receiving dexamethasone and/or rituximab monotherapy. In all patients, the overall response rate was 64.4% (complete 55.3%, partial 9.1%). Responses could not be evaluated in 219 cases (33.6%) either because of early death secondary to toxicity or lymphoma progression during therapy (n=212, 32.5%), or as a complication of patients' comorbidities (n=16, 2.5%). With a median follow up of 60 months (range 1-100), the median overall survival (OS) time was 56 months (95% CI: 38.7-73.2) with a 5-year OS rate of 50%. The causes of death were lymphoma (n=180, 27.6%), infection (n=72, 11.1%), non-infectious toxicity (n=6, 0.9%), ischemic cardiopathy (n=7, 1.1%), heart failure (n=6, 0.9%), cerebrovascular event (n=6, 0.9%), and unknown in 41 cases (6.3%). Given our prior work on the impact of serum albumin in DLBCL patients, we analyzed serum albumin levels in elderly patients with DLBCL. Hypoalbuminemia (albumin <3.5mg/dL) was associated with a higher frequency of advanced disease (n=211, 37.8% vs n=152, 27.2%; [p=0.005]), high-risk IPI score (n=77, 14.7% vs n=62, 11%; [p=0.000]), and death (n=147, 22.5% vs n=128, 19.6%; [p=0.000]). In the univariate analysis, the factors influencing mortality were: ECOG ≤1 (p=0.000, HR 1.25[95% IC: 1.0-1.4]), hypoalbuminemia (serum albumin <3.5mg/dL; p=0.031, HR 1.24 [95% IC: 1.02 -1.51]), the use of anthracyclines (p=0.002, HR 0.63, [95 % IC: 0.47 -0.84]), and no achieving a complete response (CR) to first-line treatment (p=0.000, HR 5.01 [95 %IC: 4.25 -6.0]). In the multivariate analysis, all factors remained statistically significant: ECOG ≤1 (p=0.000, aHR 1.32[95 IC: 1.1 -1.5]), hypoalbuminemia (p=0.005, aHR 1.33 [95 % IC: 1.08 -1.6]), the use of anthracyclines (p=0.006, aHR 0.66 [95 % IC: 0.49 -0.88]), and no achieving CR to first-line treatment (p=0.000, aHR 4.91 [95 %IC: 4.1 -5.7]).

Conclusions: To our knowledge, this is one of the largest real-world studies on elderly patients with DLBCL in LATAM. In this cohort, survival rates were comparable to those previously reported in the literature. This statement was also true when evaluating the response rates to first-line therapy. We found that ECOG performance status, serum albumin levels, the use of anthracycline and response to first-line therapy were all independently associated to survival. Although the main limitation of this study is its retrospective design, we report that current practices in LATAM remain appropriate for our context and known limitations, thus, this study provides some evidence to clinicians on the therapy patterns and outcomes of such therapies in elderly patients with DLBCL living in resource-limited settings.

Disclosures Vilella Martinez: *roche*: Speakers Bureau; *Merck Sharp and Dome*: Speakers Bureau; *astra zeneca*: Speakers Bureau; *TEVA*: Speakers Bureau; *Sanofi*: Speakers Bureau. **Ramirez:** *merck sharp and dome*: Speakers Bureau; *roche*: Speakers Bureau. **Quintero:** *Merck Sharp and dome*: Speakers Bureau; *Takeda*: Speakers Bureau; *astra zeneca*: Speakers Bureau; *roche*: Speakers Bureau. **Perini:** *MSD*: Consultancy, Speakers Bureau; *Merck*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Astra zeneca*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Abbvie*: Consultancy, Speakers Bureau; *Takeda*: Consultancy, Speakers Bureau; *Janssen*: Consultancy, Speakers Bureau; *Lilly*: Consultancy, Speakers Bureau. **Peña:** *Janssen*: Other: Congress Travel expenses. **Gomez-Almaguer:** *AMGEN*: Consultancy, Honoraria; *Janssen*: Consultancy, Honoraria; *Novartis*: Honoraria; *AbbVie*: Consultancy, Honoraria. **Castillo:** *Loxo*: Consultancy, Research Funding; *Kite*: Consultancy; *Pharmacyclics*: Consultancy, Research Funding; *BeiGene*: Consultancy, Research Funding; *AstraZeneca*: Consultancy, Research Funding; *Mustang Bio*: Consultancy; *Collectar*: Consultancy, Research Funding; *Abbvie*: Consultancy, Research Funding.

Table 1: Comparison of clinical characteristics and response by age group

Age group:	65- 74 years. N= 350 (100%)	>75 years N= 301 (100%)	p
Female:male	177/173	139/162	0.26
ECOG:			
0-1	229 (65.4)	171 (56.8)	0.08
> 2	121 (34.6)	130 (53.2)	
Clinical stage:			
I	65 (18.5)	58 (19.2)	0.99
II	94 (26.8)	81 (26.9)	
III	113 (32.2)	94 (31.2)	
IV	78 (22.2)	68 (22.5)	
Albumin			
>3.4 g/dL	191 (54.5)	164 (54.4)	0.66
3.4 – 2.5	79 (22.5)	80 (26.5)	
< 2.5	24 (6.8)	20 (6.6)	
Not documented	56 (16)	37 (12.2)	
Treatment:			
RCHOP	259 (74)	162 (53.8)	0.000
CHOP/RCVP/CVP	46 (13.1)	72 (23.9)	
R-mini-CHOP	22 (6.2)	39 (12.9)	
Intensive treatment	5 (1.4)	3 (0.9)	
Palliative or none treatment	18 (5.1)	25 (8.4)	
Response:			
Complete response	208 (59.4)	152 (50.5)	0.10
Partial response	34 (9.7)	25 (8.3)	
Failure	108 (30.8)	124 (41.2)	
Death	160 (45.7)	169 (56.2)	0.008
Median OS, months (95 %IC)	72 (58.1 – 85.9)	22.8 (7.1 – 38.4)	0.007

Figure 1

<https://doi.org/10.1182/blood-2023-187049>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/1748/2196344/blood-8351-main.pdf by guest on 18 May 2024